패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Cyclerion Therapeutics, Inc. 3 애널리스트 중 0 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Pete Stavropoulos	Cantor Fitzgerald & Co.
Martin Auster	Credit Suisse
Joon So Lee	Truist Securities

Cyclerion Therapeutics 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Cyclerion Therapeutics Announces an Extended Listing Compliance Period

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics Receives a Deficiency Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Recent updates

Cyclerion Therapeutics, Inc. Announces Promotion of Regina Graul to Chief Executive Officer

Cyclerion Therapeutics, Inc., Annual General Meeting, Jun 14, 2024

Cyclerion Therapeutics, Inc. Appoints Regina Graul as President

Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments

Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director

Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer

New major risk - Financial position

First half 2023 earnings released: US$5.00 loss per share (vs US$12.14 loss in 1H 2022)

New major risk - Market cap size

Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding

High number of new and inexperienced directors

J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.30 loss in 1Q 2022)

Full year 2022 earnings released: US$1.01 loss per share (vs US$1.32 loss in FY 2021)

Cyclerion Therapeutics Announces an Extended Listing Compliance Period

Price target decreased to US$4.00

Third quarter 2022 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021)

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Consensus revenue estimates fall by 54%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia

Cyclerion Therapeutics, Inc. Announces Appointment of Steven E. Hyman, M.D., to its Board of Directors

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Cyclerion Therapeutics, Inc. Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for Cy6463 in Melas Patients At Umdf Mitochondrial Medicine 2022 Symposium

Cyclerion Therapeutics Receives a Deficiency Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement

High number of new directors

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline Progress

Price target increased to US$10.50

High number of new directors

Consensus revenue estimates fall by 49%

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Full year 2021 earnings: EPS and revenues miss analyst expectations

Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline Updates

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology

Third quarter 2021 earnings released: US$0.26 loss per share (vs US$0.59 loss in 3Q 2020)

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Cyclerion Therapeutics, Inc Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Independent Director Kevin Churchwell has left the company

Second quarter 2021 earnings released: US$0.45 loss per share (vs US$0.70 loss in 2Q 2020)

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021

Cyclerion Therapeutics, Inc.(NasdaqGS:CYCN) dropped from Russell 3000E Value Index

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Cyclerion climbs on a series of insider purchases

Cyclerion Therapeutics, Inc. announced that it has received $17.896283 million in funding from EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners Management, LP, The Invus Group, LLC, Lincoln Park Capital, LLC, Polaris Partners

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

CEO & Director recently bought US$1.7m worth of stock

First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.73 loss in 1Q 2020)

Cyclerion Therapeutics, Inc. Provides Clinical Updates for its CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 in Alzheimer's Disease with Vascular Pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes

Cyclerion updates on clinical trial progress at webinar

Cyclerion Therapeutics, Inc. Announces Departure of Christopher Wright as Chief Medical Officer

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Full year 2020 earnings released: US$2.56 loss per share (vs US$4.49 loss in FY 2019)

Earnings beat expectations

New 90-day high: US$3.61

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards

New 90-day high: US$3.60

Cyclerion Therapeutics +10.5% after prelim reports

President & Chief Scientific Officer notifies of intention to sell stock

President & Chief Scientific Officer recently sold US$61k worth of stock

Cyclerion Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective January 1, 2021

Cyclerion Therapeutics announces promotions

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Chief Innovation Officer recently bought US$316k worth of stock

Third quarter 2020 earnings released: US$0.59 loss per share

Revenue and earnings beat expectations

Cyclerion Therapeutics reports Q3 results